Siga announces health canada regulatory approval of oral tpoxx®

New york, dec. 01, 2021 (globe newswire) -- siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company focused on the health security market, today announced that health canada has approved oral tpoxx® (tecovirimat) as an extraordinary use new drug. specifically, health canada has authorized the use of oral tpoxx for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.
SIGA Ratings Summary
SIGA Quant Ranking